Bronchiectasis, lymphadenopathies related to BAFF overexpression and lymphoplasmacytic cystitis as adverse events associated with prolonged use of rituximab in systemic autoimmune rheumatic diseases

Cañas, C.A.; Posso-Osorio, I.; Pérez-Uribe, V.; Erazo-Martínez, V.

doi:10.1016/j.rceng.2024.06.001

Revista Clínica Española (English Edition)

ISSN: 2254-8874

Revista Clínica Española published its first issue in 1940 and is the body of expression of the Spanish Society of Internal Medicine (SEMI).
The journal fully endorses the goals of updating knowledge and facilitating the acquisition of key developments in internal medicine applied to clinical practice. Revista Clínica Española is subject to a thorough double blind review of the received articles written in Spanish or English. Ten issues are published each year, including mostly originals, reviews and consensus documents.

Indexed in:

Current Contents / Clinical Medicine , JCR / SCI-Expanded, Index Medicus / Medline y Excerpta Medica / EMBASE

Subscribe:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2022

Impact factor 2023

2.3

Citescore

CiteScore measures average citations received per document published.

Citescore 2023

0.7

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SJR 2023

0.162

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

SNIP 2023

0.211

View more metrics

Open Access Option

Journal Information

Lee este artículo en Español

Export reference

Download PDF

More article options

Statistics

Brief Original

DOI: 10.1016/j.rceng.2024.06.001

Available online 16 June 2024

Bronchiectasis, lymphadenopathies related to BAFF overexpression and lymphoplasmacytic cystitis as adverse events associated with prolonged use of rituximab in systemic autoimmune rheumatic diseases

Bronquiectasias, adenopatías relacionadas con la sobreexpresión de BAFF y cistitis linfoplasmocítica como eventos adversos asociados al uso prolongado de rituximab en enfermedades reumáticas autoinmunes sistémicas

Download PDF

C.A. Cañasa,b,c,

Corresponding author

cacanas@icesi.edu.co

Corresponding author.

, I. Posso-Osorioa,b,c, V. Pérez-Uribec, V. Erazo-Martínezd

a Universidad Icesi, CIRAT: Centro de Investigación en Reumatología, Autoinmunidad y Medicina Traslacional, Calle 18 No. 122 -135, Cali 760031, Colombia

b Universidad Icesi, Facultad de Ciencias de la Salud, Calle 18 No. 122 -135, Cali 760031, Colombia

c Fundación Valle del Lili, Unidad de Reumatología, Cra 98 No. 18 - 49, Cali 760032, Colombia

d Fundación Valle del Lili, Centro de Investigaciones Clínicas, Cra 98 No. 18 - 49, Cali 760032, Colombia

Received 30 November 2023. Accepted 20 April 2024

Article information

Abstract

Full Text

Bibliography

Download PDF

Statistics

Tables (1)

Table 1. Possible adverse events in a cohort of 178 patients with long-term rituximab (RTX) use, type of AE, number of cases, and severity.

Abstract

Background

The long-term use of rituximab (RTX) has been gaining ground in the treatment of systemic autoimmune diseases. The adverse events (AEs) associated with its use different to infections are being reported.

Methods

A cohort of patients with SAIDs treated at a high-complexity center in Cali (southwestern Colombia) with follow-up from January 2008 to December 2022 were examined to search for potential AEs associated with prolonged use of RTX.

Results

From 178 patients with long-term use of RTX 3 (1.68%) had lymphadenopathies with lymphoid follicular hyperplasia related to BAFF overexpression, 4 (2.24%) with bronchiectasis, and 4 (2.24%) with lymphoplasmacytic cystitis.

Conclusion

Bronchiectasis, lymphoid follicular hyperplasia related to BAFF overexpression, and lymphoplasmacytic cystitis may be life-threatening long-term AEs in patients with prolonged use of RTX.

Keywords:

Anti-CD 20

Side effects

Long-term adverse events

Hypogammaglobulinemia

Resumen

Introducción

El uso a largo plazo de rituximab (RTX) ha ido ganando terreno en el tratamiento de varias enfermedades autoinmunes. Los eventos adversos (EA) asociados con su uso diferente a infecciones se han empezado a reporter.

Métodos

Se examinó a una cohorte de pacientes con EAS tratados en un centro de alta complejidad en Cali (suroccidente de Colombia) con seguimiento desde enero de 2008 hasta diciembre de 2022 para buscar posibles EA asociados al uso prolongado de RTX.

Resultados

De 178 pacientes con uso prolongado de RTX 3 (1.68%) presentaron adenopatías con hiperplasia folicular linfoide relacionada con la sobreexpresión BAFF, 4 (2.24%) con bronquiectasias) y 4 (2.24%) con cistitis linfoplasmocítica.

Conclusión

Las bronquiectasias, la hiperplasia folicular linfoide relacionada con la sobreexpresión de BAFF y la cistitis linfoplasmocítica pueden ser EA a largo plazo en pacientes con uso prolongado de RTX.

Palabras clave:

Anti-CD 20

Efectos secundarios

Eventos adversos a largo plazo

Hipogammaglobulinemia

Article

These are the options to access the full texts of the publication Revista Clínica Española (English Edition)

Member of the society

Subscriber

Contact

Member

Si es usted socio de FESEMI siga los siguientes pasos:

Diríjase desde aquí a la web de la >>>FESEMI<<< e inicie sesión mediante el formulario que se encuentra en la barra superior, pulsando sobre el candado.